Interview with Viktor Shafranskyi, General Manager, IPSEN Ukraine
Ipsen has showed some very positive results worldwide in 2010 and so far this year, specifically in non-Western…
Address: 36 Pushkinskaya street, O1004, Kiev,Ukraine
Tel: 380445026529
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2010. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology / Dysport®, endocrinology / Somatuline®, uro-oncology / Decapeptyl® and hemophilia. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patient-driven platforms, peptides and toxins. In 2010, R&D expenditure totaled more than €220 million, above 20% of Group sales. The Group has total worldwide staff of close to 4,500 employees.
Ipsen started its activities in Ukraine 20 years ago, with the promotion of a group of legacy products, the majority of which were dedicated to the treatment of gastrointestinal diseases. A couple of years later, Ipsen introduced its innovative franchise, whose three main therapeutic areas are in oncology, endocrinology, and for the treatment of neuro-muscular disorders. For the moment, the company’s strategic focus is to expand its innovative franchise and to push these medicines forward into the market.
Over the past seven years, the range of strategic products in Ipsen’s Ukraine portfolio has more than doubled. At the beginning of 2004, about 30% of sales came from the innovative franchise, whereas by the end of this year, around 60% of sales is expected to be generated by innovative medicines.
In both its targeted therapeutic areas and primary care, Ipsen has a diversified portfolio of leading drugs.
The Group’s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology, hematology), which are its primary areas of development. The Group also markets products in other therapeutic areas in which it boasts longstanding expertise (gastroenterology, cardiovascular and cognitive disorders). To a large extent, these are composed of primary care.
Ipsen has showed some very positive results worldwide in 2010 and so far this year, specifically in non-Western…
Ukraine’s bold decision to outsource public procurement of medicines to international agencies to combat rampant…
Vladimir Sayenko, founding partner, and Anzhela Makhinova, counsel, of the leading Ukrainian law firm Sayenko…
Tetiana Korotchenko, Country Representative of Crown Agents, one of the three international organizations…
Dmytro Popov, the owner, founder and CEO Elfa Group, Ukraine’s leading cosmetics manufacturer, provides his…
Dr. Maxim Sokolov, chief external specialist of the Ministry of Health of Ukraine in cardiology, principal…
Dr. Paul Melekhov, vice president Eastern Europe at Pharmascience, Canada’s third largest generic company,…
Julia Sidorova, country manager of Alvogen, a new international player to the Ukrainian market, provides insights…
Victoria Filatova, president and chairperson of the Association of Perfumery and Cosmetics of Ukraine (APCU),…
Petro Bagriy, president of the Association of Drug Manufacturers of Ukraine (AMMU), which gathers seven of the…
Robert Chagalian, country manager of Siemens Healthineers Ukraine, provides a fascinating insight into the 165-year…
Aleksandr Iavorskyi, founder and president of Biocon, Ukraine’s leading third-party logistics (3PL) company in…
Victoria Bandyk, chief operating officer of the Bioscience Group, provides insights into the unique added value and…